GH Company Profile and Key Details

Q: Who are the executives of GH?

Ms. Ines Dahne-SteuberChief Operating OfficerMr. Andy AmentSenior Vice President of OperationsDr. Craig Eagle M.D.Chief Medical OfficerDr. AmirAli Talasaz Ph.D.Co-Chief Executive Officer & DirectorMs. Jennifer HigginsVice President of Public AffairsMr. Kumud KaliaChief Information Officer & Chief Operating Officer of OncologyMr. Christopher FreemanChief Commercial OfficerDr. Helmy Eltoukhy Ph.D.Co-Founder, Co-Chief Executive Officer & ChairmanDarya ChudovaSenior Vice President of TechnologyMr. John G. SaiaChief Legal Officer & Corporation Sec.Ms. Darya ChudovaChief Technology Officer

NASDAQ : GH

Guardant Health

$95.66

0.74+0.78%

At Close 4:00 PM

65.78

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Guardant Health, Inc. (GH) stock surged +0.78%, trading at $95.66 on NASDAQ, up from the previous close of $94.92. The stock opened at $95.77, fluctuating between $93.29 and $97.49 in the recent session.

Stock Snapshot

94.92

Prev. Close

12.68B

Market Cap

93.29

Day Low

-28.14

P/E Ratio

-3.4

EPS (TTM)

-2.92

Cash Flow per Share

95.77

Open

132.6M

Number of Shares

97.485

Day High

95.22%

Free Float in %

1.34

Book Value

1.2M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 18, 2026	95.96	97.49	93.29	95.66	1.22M
May 15, 2026	97.31	98.00	92.50	94.92	1.77M
May 14, 2026	98.20	99.54	96.04	98.66	1.29M
May 13, 2026	99.14	99.14	95.60	98.47	1.64M
May 12, 2026	96.94	100.73	95.00	99.94	2.47M
May 11, 2026	95.95	97.54	94.47	96.71	2.03M
May 08, 2026	96.57	98.50	89.07	95.70	3.18M
May 07, 2026	92.81	93.90	88.89	92.26	2.37M
May 06, 2026	89.83	92.81	88.10	92.25	1.68M
May 05, 2026	91.87	93.00	87.57	89.52	1.38M
May 04, 2026	87.08	92.19	87.08	91.17	1.43M
Apr 30, 2026	84.00	87.24	79.01	87.08	2.7M
Apr 29, 2026	82.98	83.99	79.63	83.41	2.44M
Apr 28, 2026	86.04	86.60	82.07	83.09	2.8M
Apr 27, 2026	88.77	91.18	87.11	88.50	1.5M
Apr 23, 2026	88.55	89.25	83.19	87.87	1.66M
Apr 22, 2026	91.72	92.22	87.64	89.56	1.9M
Apr 21, 2026	91.07	95.18	90.28	90.36	2.47M
Apr 20, 2026	90.45	92.99	90.00	91.07	2.05M
Apr 17, 2026	86.65	91.83	85.33	90.36	2.52M

Contact Details

Palo Alto, CA 94063

United States

https://guardanthealth.com 855 698 8887

About Company

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Stock Peers

IDXX

17+3.21%

IDEXX Laboratories, Inc.$545.79 MEDP

5.4+1.30%

Medpace Holdings, Inc.$420.67 NTRA

6.18+3.32%

Natera, Inc.$192.54 ILMN

-1.03-0.72%

Illumina, Inc.$141.51 ICLR

-2.6-2.23%

ICON Public Limited Company$113.78 EXAS

Exact Sciences Corporation$104.91 BLLN

3.49+4.22%

BillionToOne, Inc.$86.12 GRAL

1.06+1.78%

GRAIL, Inc.$60.71 RDNT

1.78+3.40%

RadNet, Inc.$54.17 TWST

0.62+1.26%

Twist Bioscience Corporation$49.79

Company Overview

Guardant Health, Inc. (NASDAQ:GH) closed at $95.66 USD, gaining $0.74 (0.78%) from the previous close of $94.92. The stock is currently mid-range between its 52-week high and low $36.36 and $120.74. With a market capitalization of about $12.68 billion, Guardant Health, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.49). Key stats such as the average daily volume over the past year has been around 2.03 million shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Guardant Health, Inc. operates in the Healthcare sector and the Medical - Diagnostics & Research industry. Led by CEO Helmy Eltoukhy, the company employs approximately 1,999 people and listed since October 04, 2018. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.

Technical Performance

GH has shown sold momentum, gaining 6.79% over the past week and 75.48% over the past quarter, though year-to-date performance is up 12.46%. Short-term trend indicators are mixed aligned (SMA20 -6.31%, SMA50 -7.5%, SMA200 32.17%). The stock’s 14-day RSI is 40.83 (neutral), while the ATR of 6.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -18.86% below its high and over 180.88% above its low. Average 10-day trading volume of 1.74 million shares is below the 3-month average of 2.08 million, indicating normal recent market interest.

Valuation Metrics

Guardant Health, Inc. trades at a P/E ratio of -28.76, slightly below the S&P 500 average, with a price-to-sales ratio of 11.65 and a price-to-book ratio of -68.8 indicating negative book value, which may reflect financial stress. The P/FCF stands at -55.97, also below market averages.

Dividend & Fair Value

Guardant Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $53.03. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Guardant Health, Inc. generated EPS of -$3.31 over the past year. Five-year average earnings growth is -4.99%. Wall Street analysts project EPS growth of 60.35% annually over the next five years. The latest quarter delivered EPS of -$0.85. The next quarter is forecast at -$0.81. Next year's EPS is expected at $4.46. Analyst sentiment is bullish. Analyst rating data shows there are 27 Strong Buy ratings, 23 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $180.00 to $60.00. The high target offers 88.17% upside. The low target suggests -37.28% downside. The mean target is $104.26. This offers 8.99% upside. Guardant Health, Inc. earnings surprise history is a mixed track record. The quarter that ended May 07, 2026, missed forecasts by 80.85%. The prior quarter beat by 17.38%. Over the last six quarters, Apple has recorded several small beats. These include -17.33% in February 20, 2025.

Shareholding & Insider Activity

Guardant Health, Inc. has 124.71 million shares outstanding. The public float is 119.56 million shares, elevated short interest at 7.91% of float. This equals 9.40 million shares. The short ratio is 4.22 days. Institutional investors hold 103.78% of the float. Insiders own 4.5%. Talasaz AmirAli holds 2.10 million shares, Eltoukhy Helmy has 2.05 million shares and Bell Michael Brian has 43.60 thousand shares. Over the past six months, insider transactions show net selling. They sold 110.37 thousand shares across 21 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Guardant Health generated $563.95M in revenue, or $5.04 per share. Gross margin was 59.74%, operating margin -99.75%, and net profit margin -85.02%. Returns are negative, with ROA at -26.84% and ROE at -302.14%.
On valuation metrics, Guardant Health trades at a P/E of -28.76, P/S of 11.65 and P/B of -68.80. The current ratio is 4.68 and quick ratio is 4.39. Operationally, the company’s inventory turnover is 4.52 and cash conversion cycle is 54.91 days. Debt-to-equity is -9.26, supported by a cash flow-to-debt ratio of -0.10.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Guardant Health posted revenue of $563.95M, down slightly from $449.54M in the prior quarter. Gross profit was $336.90M (margin 59.74%). Operating income was - $562.52M (margin -99.7%). Net income was- $479.45M (EPS - $4.28).
The company ended the quarter with $1.17B in cash and short-term investments, a total debt of $1.35B, and net debt of $220.23M. Total assets were $1.79B, with equity of $158.68M. Financials further reflected weakness, with operating cash flow of - $324.98M, free cash flow of - $345.46M, and capital expenditures of - $20.49M.

Price Forecast & Outlook

Our AI price prediction model suggests that Guardant Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.61%, with price expected at $103.90 by June 01, 2026, within a range of $99.37 to $108.41 3-Month Outlook: Projected rise of 47.92%, reaching $141.50 by August 13, 2026, with a range of $139.09 to $144.86. 1-Year Outlook: Projected gain of 26.19%, with price at $120.71 by May 18, 2027, within a range of $113.03 to $126.95.

Key Takeaways

Guardant Health, Inc. (NASDAQ:GH) shares are up 12.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Guardant Health, Inc. trading at a premium to the broader market with a P/E of -28.76. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $83.86, suggesting -12.34% downside. Our AI forecast model points to short-term strength (8.61% over two weeks), a medium-term rise (47.92% over three months), and a longer-term gain (26.19% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Guardant Health, Inc. (GH) stock price?

Guardant Health, Inc. (NASDAQ: GH) stock price is $95.66 in the last trading session. During the trading session, GH stock reached the peak price of $97.49 while $93.29 was the lowest point it dropped to. The percentage change in GH stock occurred in the recent session was 0.78% while the dollar amount for the price change in GH stock was $0.74.

GH's industry and sector of operation?

The NASDAQ listed GH is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector. Guardant Health, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of GH?

Ms. Ines Dahne-Steuber
Chief Operating Officer
Mr. Andy Ament
Senior Vice President of Operations
Dr. Craig Eagle M.D.
Chief Medical Officer
Dr. AmirAli Talasaz Ph.D.
Co-Chief Executive Officer & Director
Ms. Jennifer Higgins
Vice President of Public Affairs
Mr. Kumud Kalia
Chief Information Officer & Chief Operating Officer of Oncology
Mr. Christopher Freeman
Chief Commercial Officer
Dr. Helmy Eltoukhy Ph.D.
Co-Founder, Co-Chief Executive Officer & Chairman
Darya Chudova
Senior Vice President of Technology
Mr. John G. Saia
Chief Legal Officer & Corporation Sec.
Ms. Darya Chudova
Chief Technology Officer

How GH did perform over past 52-week?

GH's closing price is 163.09% higher than its 52-week low of $36.36 where as its distance from 52-week high of $120.74 is -20.77%.

How many employees does GH have?

Number of GH employees currently stands at 1,999.

Link for GH official website?

Official Website of GH is: https://guardanthealth.com

How do I contact GH?

GH could be contacted at phone 855 698 8887 and can also be accessed through its website. GH operates from 505 Penobscot Drive, Palo Alto, CA 94063, United States.

How many shares of GH are traded daily?

GH stock volume for the day was 1.2M shares. The average number of GH shares traded daily for last 3 months was 2.03M.

What is the market cap of GH currently?

The market value of GH currently stands at $12.68B with its latest stock price at $95.66 and 132.6M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1999
Beta	1.69
Sales or Revenue	$563.95M
5Y Sales Change%	0.689%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Diagnostics & Research

GH Company Profile and Key Details

Guardant Health

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways